Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1534706 participants
OBSERVATIONAL
2021-01-01
2022-01-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To do so we performed a disproportionality analysis adjusted on age class, sex, region and type of reporter in VigiBase®, the WHO pharmacovigilance database, restricted to data from 01/01/2021 to 26/01/2022 to assess the association between all COVID-19 vaccines on the market and malaise. Demographic data were also analyzed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2018)
NCT03392207
Immune Response and Risk of Side Effects After Influenza Vaccination in Athletes
NCT03654937
Surveillance for Adverse Events Following Pandemic H1N1 Immunization
NCT01289418
Surveillance for Adverse Events Following Influenza Immunization
NCT01318876
Measuring the Healthy Pediatric Inflammatory Response to Vaccination.
NCT04112355
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients presenting a malaise after the vaccination by any vaccine
SARS-CoV-2 vaccine
SARS-CoV-2 vaccination
Patients presenting any other adverse event after the vaccination by any vaccine
SARS-CoV-2 vaccine
SARS-CoV-2 vaccination
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SARS-CoV-2 vaccine
SARS-CoV-2 vaccination
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Caen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Caen University Hospital, Department of Pharmacology
Caen, Normandy, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pharmaco 20220203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.